Insilico Medicine's stock plunged 6.49% during intraday trading, extending recent losses as the company faces dual pressures from dashed market expectations and approaching shareholder lock-up expirations.

The decline follows the company's voluntary announcement clarifying it currently has no definite plans for a secondary listing in Abu Dhabi, disappointing investors who had anticipated such a move would broaden the company's international financing channels and deepen its Middle East strategic positioning.

Additionally, having listed on the Hong Kong Stock Exchange in December last year, Insilico Medicine has now entered the June lock-up expiry window, with certain cornerstone investors and employee option restricted shares approaching their release dates. Market concerns over potential selling pressure from these unlocked shares have intensified disposal activity, contributing to the stock's downward trajectory.